Unlock instant, AI-driven research and patent intelligence for your innovation.
Effect of atorvastatin on preparation of drug for treating pulmonary hypertension
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of atorvastatin and pulmonary arterial hypertension, applied in the field of action of drugs, can solve problems such as reduction of systemic circulation pressure
Inactive Publication Date: 2014-04-02
邢西迁
View PDF0 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] At present, the drugs for the treatment of pulmonary arterial hypertension mainly include prostacyclin analogs, phosphodiesterase inhibitors, endothelin receptor antagonists and inhaled nitric oxide, but these drugs are only effective for some patients with pulmonary arterial hypertension, and can reduce systemic circulation pressure side effects
However, there is no report about whether statins affect the expression of NF-kB in the lung tissue of rats with pulmonary arterial hypertension.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0106] The preparation of embodiment 1 tablet of the present invention
[0110] 100 g of the above-mentioned atorvastatin and 300 g of starch are fully mixed, added with starch paste to make a suitable soft material, granulated, dried at 100 degrees, granulated, added with calciumstearate, compressed into 1000 tablets.
[0111] The dosage of the medicament of the present invention is 1 tablet / day as a starting dose, and the dosage range is 1-6 tablets / day, and it can be taken orally once a day.
Embodiment 2
[0112] The preparation of embodiment 2 capsules of the present invention
[0113] a) The preparation formula is atorvastatin 200g, lactose 350g, oxidized vegetable oil 3g
[0114] b) Preparation method:
[0115] 200g of atorvastatin and 350g of lactose are fully mixed, added with starch paste to make a suitable soft material, granulated, dried at 100 degrees, granulated, added with hydrogenated vegetable oil, mixed evenly, filled into capsules to make 1000 capsules.
[0116] The dosage of the medicine of the present invention is 1 capsule / day, the dosage range is 1-3 capsules / day, and it can be taken orally once a day.
Embodiment 3
[0117] The preparation of embodiment 3 granules of the present invention
[0121] 200 g of the above-mentioned atorvastatin and 800 g of sucrose are fully mixed, added with water to make a suitable soft material, granulated, dried at 100 degrees, granulated, and bagged to make 1000 bags of granules.
[0122] The dosage of the medicine of the present invention is 1 bag / day, the dose range is 1-3 bags / day, and it can be taken orally once a day.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertensionlung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary arteryhigh pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.
Description
technical field [0001] The present invention relates to a new application of medicine, in particular, relates to the effect of atorvastatin in the preparation of medicine for treating pulmonary arterial hypertension. Background technique [0002] Pulmonary hypertension is a common and serious complication of chronic lungdisease, characterized by increased pulmonary vasoconstriction reactivity and pulmonary vascular structural remodeling. Its formation mechanism has not yet been fully explained. Current studies have shown that the enhanced responsiveness of pulmonary vasoconstriction is caused by vascular endothelial dysfunction. The imbalance between vasodilation substances such as nitric oxide and vasoconstrictor substances such as endothelin is a feature of vascular endothelial dysfunction; while pulmonary vascular structure reconstruction is mostly These factors stimulate the proliferation of pulmonary vascular smooth muscle cells, the increase of extracellular matrix c...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
